Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Celerion | National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Desmetramadol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2020
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Celerion | National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Desmetramadol is G-Protein Biased Opioid Receptor Agonist: Syntrix
Details : Findings could put desmetramadol in pivotal high-value position for safer opioid prescribing.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 04, 2020
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : DF/Net Research | National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy
Details : Omnitram is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Neuropathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2018
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : DF/Net Research | National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : PRA Health Sciences | DF/Net Research | ITT Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omnitram is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2017
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : PRA Health Sciences | DF/Net Research | ITT Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Omnitram Pharmacokinetic Study In Healthy Volunteers
Details : Omnitram is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2014
Lead Product(s) : Desmetramadol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable